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Tofurtherinvestigatepathogenesisandpathogenicprocessoftype2diabetesmellitus(T2DM),wecomparedtheurinarymetabolic
proﬁling of Zucker obese and Goto-kakizaki (GK) rats by NMR-based metabonomics. Principal component analysis (PCA) on
urine samples of both models rats indicates markedly elevated levels of creatine/creatinine, dimethylamine, and acetoacetate, with
concomitantly declined levels of citrate, 2-ketoglurarate, lactate, hippurate, and succinate compared with control rats, respectively.
Simultaneously, compared with Zucker obese rats, the GK rats show decreased levels of trimethylamine, acetate, and choline, as
well as increased levels of creatine/creatinine, acetoacetate, alanine, citrate, 2-ketoglutarate, succinate, lactate, and hippurate. This
study demonstrates metabolic similarities between the two stages of T2DM, including reduced tricarboxylic acid (TCA) cycle and
increased ketone bodies production. In addition, compared with Zucker obese rats, the GK rats have enhanced concentration of
energy metabolites, which indicates energy metabolic changes produced in hyperglycemia stage more than in insulin resistance
stage.
1.Introduction
Diabetes mellitus is the most common metabolic disease in
the world. Over 90 percent of patients with diabetes belong
totype2diabetes(T2DM)[1].T2DMisametabolicdisorder
characterized by a chronic hyperglycemia with disturbances
of carbohydrate, fat, and protein metabolism resulting from
defects in insulin secretion or insulin action [2]. Although
the pathogenesis of the disease remains unclear, insulin
resistance plays an important role in its pathogenic process,
which precedes the clinical development of diabetes by 10–
20 years [3, 4]. However, little is known about what this
inherited metabolic relation between the two stages.
In order to give new insight into diabetic process itself,
as well as conduct clinical instruction, it is necessary to
clarify the global metabolic alteration that characterizes its
progression. Metabonomics, deﬁned as “the quantitative
measurement of the dynamic multiparametric metabolic
response of living systems to pathophysiological stimuli or
genetic modiﬁcation” [5], is increasingly being applied to the
study of disease, especially in metabolic disease [6]. With this
technology Williams and his colleagues detected diﬀerences
between plasma [7, 8] and urinary [9, 10] metabolic proﬁles
of Zucker obese and control rats. The metabolic changes
includedthedecreasedleveloftaurine,togetherwithchanges
in the relative proportion of tricarboxylic acid (TCA) cycle.
Salek et al. [11] compared metabolic similarities among
diﬀerent type 2 diabetic models (rat and mouse) and
human suﬀerers and identiﬁed perturbations in metabolism
common to all three species, except changes of TCA cycle,
perturbations in nucleotide metabolism were also deter-
mined. Wijekoon et al. [12] compared metabolic changes of
amino acids in two stages of Zucker diabetic rat: prediabetic
insulin-resistant and hyperglycemia stage. They found that
concentrations of many gluconeogenic amino acids were
lower at both stages whereas the levels of the branched-
chain amino acids were elevated. Although a number of2 Journal of Biomedicine and Biotechnology
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Figure 1: 1H NMR spectra of urinary samples obtained from
the GK rat (a) and Zucker obese rat (b), respectively. (1) leucine
+ isoleucine; (2) β-hydroxybutyrate; (3) lactate; (4) alanine; (5)
acetate; (6) glutamate; (7) N-acetylglycoprotein; (8) methonine; (9)
acetoacetate; (10) succinate; (11) 2-ketoglutarate; (12) citrate; (13)
dimethylamine; (14) trimethylamine; (15) creatine + creatinine;
(16) taurine; (17) taurine; (18) glucose; (19) creatinine; (20)
allantoin; (21) urea; (22) phenylalanine; (23) hippurate; (24) N-
methylnicotinamide; (25) formate.
diabetes-related studies have been reported in recent years,
the similarities and diﬀerences of metabolic changes between
stages of insulin resistance and T2DM remain unclear. To
further understand the pathogenic process of T2DM and
identify its characteristics, we chose two relevant rat models:
the Zucker obese rat and Goto-kakizaki (GK) rat, which
represent two pathogenetic processes of T2DM, respectively:
insulin resistance and hyperglycemia stage. Then in the
present study, the urinary metabolic proﬁles of Zucker
obese rats and GK rats were compared by NMR-based
metabonomics, and we aimed to ﬁnd the relation between
the two diabetic stages.
2.MaterialsandMethods
2.1. Subjects. Spontaneously diabetic male GK rats (Shang-
hai Laboratory Animal Co., Ltd. Shanghai, China; 60 days
of age; n = 8) weighed 263.0 ± 5.5g at the beginning of
experiments. The corresponding control animals were male
Wistar rats with similar age. Male Zucker obese rats (fa/fa;
weighed 421.3 ± 10.5g; n = 5) and their lean littermates
(fa/+), aged 8 weeks, were obtained from the Institute of
LaboratoryAnimals,KyotoUniversity,andmaintainedatthe
Shanghai Institute of Materia Medica, Chinese Academy of
Sciences.
Animals were kept in a barrier system with regulated
temperature and humidity and on a 12/12h light-dark cycle
with lights on at 08:00 AM. During the whole experimental
process, rats were fed with certiﬁed standard rat chow and
tap water ad libitum. All animal treatments were strictly in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals.
2.2. Collection and Preparation of Samples. Urinary samples
w e r ec o l l e c t e d ,f o r2 4h o u r s ,e a c ho ft h eZ u c k e ra n dG Kr a t s
inindividualurinecollectioncagesovericeinto0.1mLof1%
sodium azide solution. The urine samples were centrifuged,
and the supernatant was stored at −80◦C before analysis.
Prior to NMR analysis, urine samples were thawed, and
300μL of aliquots were mixed with 300μL of phosphate
buﬀer (0.2mol/L Na2HPO4/NaH2PO4, pH 7.4) to minimize
variations in pH. The samples were centrifuged at 12 000g
for 10 minutes at 4◦C to separate any precipitate. Aliquots
of 500μL of the resulting supernatants were moved into
5mm NMR tubes containing 100 μLs o l u t i o no f2 , 2  ,3,3 -
deuterotrimethylsilylproprionic acid (TSP) in D2O (the
ﬁnal concentration is 1.5mmol/L). D2Op r o v i d e daﬁ e l d
frequency lock. TSP was used as the chemical shift reference.
2.3. 1H NMR Spectroscopic Analysis of Samples. All NMR
spectra were recorded at 25◦C on a Varian Unity INOVA
600MHz NMR spectrometer equipped with a triple res-
onance probe and z-axis pulsed ﬁeld gradient. For urine
samples,one-dimensionalspectrawereacquiredusingaone-
dimensional NOESY pulse sequence with water suppression
during therelaxationdelayof2seconds,andthemixing time
of 120ms. Sixty-four free induction decays were collected
into 32K data points with a spectral width of 10000Hz, an
acquisition time of 1.64 seconds and a total pulse recycle
delay of 5.76 seconds. The free induction decay (FID) was
zeroﬁlled to 64K and multiplied by an exponential line-
broadening function of 0.3Hz prior to Fourier transforma-
tion. Resonances assignments were performed based on the
extant literatures [13]a n d2 D1H-1H COSY and TOCSY
spectra (data not shown).
2.4. Multivariate Pattern Recognition Analysis of 1HN M R
Spectra. In order to exploit all the metabolic information
embedded in the spectra, all NMR spectra were data reduced
to 241 integrated regions of equal width of 0.04ppm
(buckets) corresponding to the region of δ 10.0 to 0.4 using
the VNMR 6.1C software package (Varian, Inc) prior to
statistical analysis. Each segment consisted of the integral
of the associated NMR region except the region of δ 6.2–
4.6 (containing the residual water and urine resonance)
that was set to zero integral in the analysis. Following a
preliminary PCA analysis, regions including δ 5.2, δ 4.6, δ
3.4–3.9, and δ 3.2 of all spectra were also removed due to
the presence of conspicuous glucose metabolite resonances.
The remaining spectral segments for each NMR spectrum
were normalized to the total sum of the spectral intensity to
partially compensate for diﬀerences in concentration of the
samples.
The normalized integral values were then subjected
to multivariate analysis as variables for the multivariateJournal of Biomedicine and Biotechnology 3
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Figure 2: (a)-(b) PCA scores plot (PC1/PC2) and corresponding loading plot based on the 1H NMR spectra of urine samples from Zucker
lean rats (∗) and Zucker obese rats (), respectively. (c)-(d) PCA scores plot (PC1/PC2) and corresponding loading plot based on the 1H
NMR spectra of urine samples from Wistar rats () and GK rats (•), respectively.
pattern recognition analysis using version 10.5 of SIMCA-
P software package (Umetrics, Ume˚ a, Sweden). Principal
component analysis (PCA) was performed to diﬀerentiate
between the groups of samples. Data were visualized with
the PC scores plot of the ﬁrst two or three principal
components(PC1,PC2,orPC3)toprovidethemosteﬃcient
2D or 3D representation of the information contained in
the data set, in which each point represents an individual
spectrum of a urine sample. The corresponding loading
plots, in which each point represents a single NMR spectral
region segment, are used to identify which spectral variables
contribute to the separation of the samples on the scores
plot.
Meanwhile, in order to detect signiﬁcant diﬀerences
between metabolic changes, unpaired t-test was carried out
for the comparison of integral values of spectral variables. P-
value of less than .05 was considered statistically signiﬁcant.
3. Results and Discussion
As represented a widely used rodent model of obesity and
insulin resistance, the Zucker obese rat (fa/fa)i sal e p t i n
deﬁcient stain, characterized by obesity, insulin resistance,
hyperinsulinaemia, and dyslipidaemia [14]. The GK rat is
a spontaneous type 2 diabetic model [15], which shows
the main features of the metabolic, hormonal, and vascular
disordersusuallydescribedinT2DM[16].Herewedescribed
the application of 1H NMR-based metabonomics to investi-
gate the urinary metabolic proﬁles in both rat models related
to T2DM.
3.1. Analysis of Metabonomic Data. Typical 1H NMR spectra
ofurinarysamplesfromZuckerobeseandGKratsareshown
in Figure 1, in which the main resonances are assigned. In
order to illustrate the diﬀerences in the metabolic proﬁle,4 Journal of Biomedicine and Biotechnology
Table 1: Summary of the changes in relative amounts of urine metabolites of diﬀerent group rats indicated by 1H NMR spectra (mean ±
SD).
δ 1H Metabolites Zucker lean Zucker obese Wistar GK
1.33 Lactate 1.67 ±0.12 1.10 ±0.11
∗∗ 2.97 ±0.95 1.86 ±0.17
∗∗
1.46 Alanine 0.44 ±0.01 0.37 ±0.03
∗∗ 0.63 ±0.07 0.66 ±0.04
1.93 Acetate 0.98 ±0.19 1.32 ±0.16
∗∗ 1.54 ±0.68 1.04 ±0.10
∗
2.14 Methionine 0.73 ±0.07 0.75 ±0.08 0.95 ±0.06 1.37 ±0.12
∗∗
2.26 Acetoacetate 0.72 ±0.17 0.80 ±0.09
∗ 0.95 ±0.10 1.17 ±0.36
∗∗
2.43 Succinate 1.26 ±0.11 1.11 ±0.15
∗∗ 2.03 ±0.34 1.87 ±0.26
2.46 2-ketoglutarate 1.22 ±0.27 1.04 ±0.10
∗∗ 3.93 ±0.56 3.13 ±0.49
∗
2.52, 2.67 Citrate 1.92 ±0.26 1.55 ±0.37
∗∗ 2.80 ±0.74 1.78 ±0.46
∗∗
2.72 Dimethylamine 1.23 ±0.58 1.84 ±0.17
∗ 1.25 ±0.18 1.69 ±0.13
∗∗
3.06 Creatine 2.62 ±0.49 3.52 ±0.25
∗∗ 5.16 ±0.33 5.82 ±0.35
∗∗
3.20 Choline 0.61 ±0.04 1.44 ±0.91
∗∗ 1.00 ±0.15 0.99 ±0.10
3.26, 3.42 Taurine 2.12 ±0.43 2.88 ±0.38
∗∗ 2.53 ±0.21 —
7.34 Phenylalanine 0.50 ±0.04 0.50 ±0.10 0.51 ±0.04 0.70 ±0.22
∗
7.55, 7.64 Hippurate 0.87 ±0.05 0.23 ±0.05
∗∗ 0.98 ±0.22 0.75 ±0.08
∗
∗P <. 05 and ∗∗P <. 01 compared with their corresponding control rats, respectively.
NMR spectra were further segmented and subjected to
PCA. The glucose resonances were excluded before the PCA
described for all spectra data, for the increase in urinary
glucose concentration was, well documented in GK rats [11].
In the scores plot of PCA (Figure 2(a)), the Zucker obese
rats are separated from the Zucker lean rats in the direction
of PC1, which indicates changes of the metabolic patterns
between the two groups. The contributions of diﬀerent
regions of the spectra to the separation are illustrated in
the loading plot (Figure 2(b)). Similar to the case of Zucker
obese rats, scores plot of GK and its control rats revealed
the complete separation, too (Figures 2(c) and 2(d)).
Then the comparison of metabolic changes of both model
rats compared with respective control rats is described in
Table 1.
3.2. Comparing the Metabolic Changes of Both Models.
From the metabonomic data, we could ﬁnd that many of
metabolic changes in Zucker obese rats were consistent with
the GK rats, including the decreased levels of citrate, 2-
ketoglurarate, lactate, hippurate, and succinate, as well as
the increased levels of creatine/creatinine, dimethylamine
and acetoacetate. The results indicate similar states of
metabolic changes between the two stages of diabetes,
which is consistent with the changes of some amino acids
concentration in Zucker diabetic rats previously reported in
[12].
TheenergyneededforthebodytofunctionrequiresATP,
which primarily comes from glycolysis, glucose oxidation
and lipid oxidation. Under normal physiological conditions,
multiple substrates can be utilized, such as glucose, amino
acids, ketone bodies, and fatty acids [17]. In GK and Zucker
obeserats,thedecreasedlevelsofcitrate,2-ketoglutarate,and
succinate, which are intermediates of the TCA cycle localized
mainly in mitochondria, are indicative of alterations in
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Figure 3: Combined analysis of the metabolomic dataset based on
the 1H NMR spectra of urine samples from Zucker obese rats (),
Zucker lean rats (∗), GK rats (•), and Wistar rats (), respectively.
energy metabolism. It is known that the mitochondria pro-
ducemore than 90% of energyATP by ox-phos [18].Serkova
et al. had demonstrated the signiﬁcant decrease of hepatic
ATP./ADP ratio in Zucker obese rats [19], which probably
implied the occurrence of impairment in mitochondrial
function in diabetic state [20]. The alterations of the organic
acids levels were consistent with change of related enzyme
activity, such as inhibition of pyruvate kinase, glucokinase,
andphosphofructokinaseinthehyperglycemiastate[21,22].
The results of both models, especially of Zucker obese rats,
indicate that the mitochondrial dysfunction occurs at the
whole pathogenetic process of T2DM.
From the results, we also determined the increased
levels of acetoacetate, which suggests the shift in energyJournal of Biomedicine and Biotechnology 5
metabolism towards the formation and utilization of ketone
bodies. And the increased ketone bodies production might
be explained by the production of fatty acids, which were
signiﬁcantly increased both in Zucker obese and GK rats
[23]. Also was found it the decreased level of lactate in
urinary samples of both models. Our results were consistent
with the GK and STZ administration for 1 month diabetic
rats [24], in which they attributed the decrease of lactate to
the production of ATP. The metabolic changes indicate the
similarities of glucose and ketone bodies metabolism in the
two stages of T2DM.
Lipid intermediary metabolites, such as choline and
dimethylamine,arepresentintheurine,serum,andmultiple
tissues of mice, rats, and humans. One of the principle roles
of methylamines is to act as nonperturbing renal osmolytes
[25]. Our study showed that both model rats excreted
higher concentrations of methylamines in the urine. The
upregulation of the methylamine pathway in vivo might be
linked to the osmotic compensation for raised blood glucose
concentrations, or it might be indicative of a renal papillary
dysfunction in diabetic state [26].
It was reported that the combined elevation of taurine
and creatine levels had been regarded as biomarkers for liver
damage [27]. Creatine is synthesized and metabolized in the
liver, so its change of concentration reﬂects the alteration of
liver function. Increased level of taurine in Zucker obese rats
was also found in the study. Because in 1H NMR spectra
of urine samples, resonance peaks of taurine (δ 3.26 and δ
3.42)overlappedwithglucose,andthelatterwassigniﬁcantly
elevated in GK rats (Figure 1). As a result, we could not
determine its change in GK rats. As the most abundant free
amino acid in many tissues, taurine plays many physiologic
and pathologic roles in vivo. Except for indication of
liver dysfunction after administration of hepatotoxins [27],
taurine was also a potent endogenous antioxidant, which
showed protective eﬀects against oxidative stress in diabetic
rats [28]. In addition it was reported that taurine could
inﬂuence blood glucose and insulin levels and play a role in
the function and integrity of pancreatic β-cells, the site of
insulin secretion [29].
3.3. A Combination of Two Strain Rats. A 3D-PCA scores
plot of two stages of T2DM was built using the NMR data
of urine samples from both model rats and their control
(Figure 3). In the plot, there is distinct separation between
the diﬀerent samples, which indicated diﬀerences of the
metabolic patterns among diﬀerent groups. Interestingly, the
ﬁgure shows that Zucker obese and lean rats almost lay in the
s a m eq u a d r a n t ,a sw e l la sG Ka n dW i s t a rr a t sl a yi na n o t h e r ,
which indicated the similar metabolic pattern in the similar
strain of rats. From the results, we could draw the conclusion
that the metabolic changes caused by strain-related variation
were larger than pathological state.
By comparison of two model rats, a number of metabolic
alterations were identiﬁed in GK rats: (1) increased lev-
els of creatine/creatinine, 2-ketoglutarate, lactate, citrate,
hippurate, acetoacetate,alanine, and succinate; (2) decreased
levels of trimethylamine, acetate, and choline compared with
Zucker obese rats. The increased concentration of energy
metabolites, such as TCA intermediates (2-ketoglutarate,
succinate, and citrate), lactate, and acetoacetate, reﬂected
energy metabolic changes produced by hyperglycemia stage
more than in insulin resistance stage. The results indicated
in the state of hyperglycemia that the glucose and energy
metabolic changes were signiﬁcantly active than those in the
state of insulin resistance.
Other perturbations of interest included increased
methylamines and acetate metabolites in Zucker obese rats.
The reason of elevation of the metabolites might be the lipid
metabolic activity in Zucker obese rats more than in GK rats.
Inaddition,theelevationofacetatelevelitselfmaycontribute
to impaire in renal function [9]. Compared with the GK
rats, reduced urinary creatinine was shown in Zucker obese
rats, which reﬂected altered renal tubular function in the rats
[30]. These results indicated that, compared with GK rats,
Zucker obese rats might be more inclined to develop diabetic
nephropathy. However, more data are required to support
this hypothesis.
4. Conclusion
Toourknowledgethisworkﬁrstlycomparedmetaboliclevels
in the two stages of pre- and diabetes by metabonomic tech-
nology. Many of the changes observed in insulin resistance
stage were similar to those found in hyperglycemia stage.
However, a combination of the urine samples of all the
rats indicated that the metabolic changes caused by strain-
related variation were larger than those in pathological state.
In addition, compared with Zucker obese rats the, GK rats
had enhanced energy metabolic pathways, which indicated
energy metabolic changes produced in hyperglycemia stage
more than in insulin resistance stage. The results will be of
potential beneﬁt to understanding the pathogenic process of
T2DM and oﬀers important information for the diagnosis
and treatment of the disease.
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